Corcept股票：并不便宜，但有真实结构性增长支撑（纳斯达克：CORT）
· seekingalpha.com
Corcept Therapeutics正发展为多引擎增长平台，受库欣综合征适应症扩展及Lifyorli推动。在此阅读更多关于CORT股票的内容。
The way I see it, Corcept Therapeutics Incorporated ( CORT ) is transitioning from a single-franchise endocrine story into a multi-engine growth platform. Now, ...